Can Enveric's Newly Patented Compounds Transform Addiction and ADHD Treatment? Patent Details Revealed

EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD

EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD Image Cannabis News February 26, 2025 Enveric Biosciences has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, ADHD anxiety, and other neuropsychiatric disorders, potentially offering new therapeutic avenues for Medical Canna…

Japan Patent Allowance for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) the Company developing a New Class of Synthetic Anti-Infectives, is pleased to announce the receipt of a notice of allowance from the Japan Patent Office for Patent Family 4 for Recce’s Anti-infectives, expiry 2041. The Japan Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably:Process for preparation of RECCE® anti-infectivesUse of R327/R529 for th…

Enveric Biosciences' Patent For Non-Hallucinogenic Psychedelic Compounds

In a significant development for mental health treatments, Enveric Biosciences (NASDAQ: ENVB) has secured its first U.S. patent for a novel series of compounds that could transform how we approach neuropsychiatric disorders. The company’s EVM401 Series represents a growing class of psychedelic-inspired therapies designed to provide the benefits of traditional psychedelics without the hallucinogenic effects that can limit their clinical use. Brea…

Can Enveric's Newly Patented Compounds Transform Addiction and ADHD Treatment? Patent Details Revealed

Enveric's patented mescaline derivatives show promising interaction with key brain receptors involved in opioid withdrawal, ADHD, anxiety, and depression treatment.